Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes.

Autor: Tan D; Clinic for Lymphoma, Myeloma and Blood Disorders, Mount Elizabeth Novena Hospital, Singapore. Electronic address: daryl.tan@dcltan.com., Chan JY; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Wudhikarn K; Division of Hematology and Center of Excellence in Translational Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Wong RSM; Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong., Poon L; Department of Hematology-Oncology, National University Cancer Institute Singapore, Singapore., Norasetthada L; Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand., Huang TC; Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan., Tse E; Department of Medicine, University of Hong Kong, Hong Kong.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Sep; Vol. 24 (9), pp. e320-e328. Date of Electronic Publication: 2024 May 20.
DOI: 10.1016/j.clml.2024.05.013
Abstrakt: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for around 30-60% of all cases. The management of DLBCL in Asia has several unmet needs due to the diversity of the population, the heterogeneity of local clinical guidelines for DLBCL and the wide disparity in resources and healthcare systems across different regions. Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) is widely recognized as the standard first-line treatment for DLBCL; however, alternative regimens are required to improve patient outcomes in challenging subtypes, such as patients with high International Prognostic Index scores, old/frail patients, and patients with double-hit and double-expressor DLBCL or concurrent central nervous system disease. This review article draws from the expertise of practicing hematologists/oncologists in the region, with the aim of integrating data from current scientific evidence to address the unmet needs and unique socioeconomic challenges faced by challenging high risk patient groups in the Asia-Pacific region.
Competing Interests: Disclosure Daryl Tan: Grant/Research support: Novartis, Janssen. Speaker's bureau: BMS, Novartis, Pfizer, Roche, Takeda, Janssen. Consultant: Amgen, AstraZeneca, BMS, GSK, Takeda, Pfizer, Roche. Jason Yongsheng Chan: Consultant/Speaker's Bureau: Antengene, Takeda, AstraZeneca, Novartis, Roche, MSD, Specialised Therapeutics, DKSH/Beigene, Janssen, AbbVie. Grant/Research support: SymBio Pharmaceuticals, Scinnohub Pharmaceuticals, ArcherDX/Invitae, Miltenyi Biotec, STEMCELL Technologies, MGI Technologies, BGI Research, Twist Biosciences, Agilent Technologies, Illumina, BioSyngen, NovogeneAIT. Travel support: AstraZeneca, Janssen, Amgen. Kitsada Wudhikarn: Advisory with honorarium: Beigene. Raymond Siu Ming Wong: Grant/Research support: AbbVie, Acerta, Alexion, Amgen, Apellis, Astella, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celgene, Daiichi-Sankyo, GSK, Janssen, Kartos, Morphosys, MSD, Novartis, Pfizer, Regeneron, Roche. Speaker's bureau: Astella, Amgen, Bayer, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Novartis, Pfizer, Roche. Consultant: Alexion, Amgen, Astella, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche. Limei Poon: Research support: Regeneron. Lalita Norasetthada: This author has no COIs to declare. Tai-Chung Huang: Honoraria: HOPE Foundation for Cancer Care, Janssen, MundiPharma, Novartis, Roche. Consulting or advisory role: AbbVie, Antengene, AstraZeneca, Beigene, Roche, Takeda. Research funding: NTUH Hematology Clinical Research Grant, Yonglin Foundation. Speakers’ bureau: AbbVie, Antengene, Bristol-Myers Squibb, Celltrion, Hematology Society of Taiwan, MundiPharma, Novartis, Roche, Takeda, TTY. Travel, accommodations, expenses: Janssen, MundiPharma, Roche, Takeda. Eric Tse: Consultant and research support: MSD. Research support from AstraZeneca and Janssen. Advisory with honorarium: Abbvie, Beigene, Janssen, Pfizer, Roche.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: